
|Videos|May 12, 2022
Side Effects of IO/TKI Treatment Regimens for Renal Cell Carcinoma
Author(s)Thomas E. Hutson, DO, PharmD
Thought leaders explain how they dose IO/TKI treatment regimens to better manage side effects in patients with renal cell carcinoma.
Advertisement
Episodes in this series

Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
Achieving a “Functional Cure” With Multiple Myeloma Therapy
5





























































